Recombinant Human VSIG3 C-Terminal Fc Chimera Protein, CF

Catalog #: 10075-VS Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
10075-VS-050

Recombinant Human VSIG3 C-Terminal Fc Chimera Protein Bioactivity

2 Images

Product Details

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human VSIG3 C-Terminal Fc Chimera Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its ability to inhibit anti-CD3 antibody induced IL-17 or IFN-gamma secretion by human peripheral blood mononuclear cells (PBMC). The ED₅₀ for this effect is 1-6 μg/mL.

Source

Chinese Hamster Ovary cell line, CHO-derived human VSIG3 protein

Human VSIG3 (Pro144-Gly241) Accession # Q5DX21	IEGRMD	Human IgG₁ (Pro100-Lys330)
N-terminus		C-terminus

Accession #

Q5DX21

N-terminal Sequence
Analysis

Pro144

Structure / Form

Disulfide-linked homodimer

Predicted Molecular Mass

37 kDa

SDS-PAGE

41-51 kDa, reducing conditions

Product Datasheets

10075-VS

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

10075-VS

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 200 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity

View Larger

Recombinant Human VSIG3 C-Terminal Fragment Fc Chimera (Catalog # 10075-VS) inhibits anti-CD3 antibody induced IFN-gamma secretion by human peripheral blood mononuclear cells. The ED₅₀ for this effect is 1-6 μg/mL.

SDS-PAGE

View Larger

2 μg/lane of Recombinant Human VSIG3 C-Terminal Fragment was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 41-51 kDa and 80-100 kDa, respectively.

Reconstitution Calculator

Background: VSIG3

VSIG3, also known as IGSF11, BT-IgSF, and CLMP, is an approximately 50 kDa transmembrane adhesion protein (1). Mature human VSIG3 consists of a 219 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane segment, and a 169 aa cytoplasmic domain (2). Within the ECD, human VSIG3 shares 95% aa sequence identity with mouse and rat VSIG3. Human ECD contains two tandem Ig-like domains, and this product includes only the C-terminal Ig-like domain (aa 144-241). Alternative splicing generates additional isoforms with a substituted signal peptide that may also have a deletion in the second Ig-like domain (3). VSIG3 is expressed on epithelial and endothelial cells, neurons and glial cells, and platelets (2-4). It localizes to epithelial tight junctions and mediates homophilic in trans cell adhesion (3-5). VSIG3 also localizes to neuronal postsynaptic densities where it recruits the GluA1 and GluA2 subunits of AMPA receptors and supports excitatory synaptic transmission (6). The short isoform can be up-regulated in gastric cancer (7). In zebrafish, VSIG3 is expressed in melanophores and plays a role in the development and patterning of pigment cells (8).

References

Schreiber, J. et al. (2014) Adv. Neurobiol. 8:21.
Suzu, S. et al. (2002) Biochem. Biophys. Res. Commun. 296:1215.
Katoh, M. and M. Katoh (2003) Int. J. Oncol. 23:525.
Raschperger, E. et al. (2004) J. Biol. Chem. 279:796.
Harada, H. et al. (2005) J. Cell. Physiol. 204:919.
Jang, S. et al. (2016) Nat. Neurosci. 19:84.
Watanabe, T. et al. (2005) Cancer Sci. 96:498.
Eom, D.S. et al. (2012) PLoS Genet. 8:e1002899.

Long Name

V-Set and Immunoglobulin Domain Containing 3

Entrez Gene IDs

152404 (Human); 207683 (Mouse); 303926 (Rat); 102146257 (Cynomolgus Monkey)

Alternate Names

Brain and testis-specific immunoglobulin superfamily protein; BTIGSF; Bt-IGSF; cancer/testis antigen 119; CT119; CXADR like 1; CXADRL1; IGSF11; Igsf13; immunoglobulin superfamily member 11; immunoglobulin superfamily, member 11; MGC35227; V-set and immunoglobulin domain containing 3; V-set and immunoglobulin domain-containing protein 3; VSIG3; VSIG3brain and testis-specific immunoglobin superfamily protein